$21.08
−1.03%Oct 1, 2026, 20:15 UTC
Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.
Source:Sep 24, 2026, 20:15 UTC
Nanobiotix reported its operational progress and financial results for the first half of 2026.
Source:Sep 14, 2026, 06:00 UTC
Nanobiotix announced complete full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer.
Source:Jun 2, 2026, 20:30 UTC
Nanobiotix provided an operational update and reported financial results for the first quarter of 2026.
Source: